Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 34

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 16
Chunk 34
---
,887,683

    $
    —

    Incremental fair value of the Class D Common Stock Warrants in connection with the Class D Warrant Inducement
     
    $
    939,679

    $
    —

    Equity issuance costs in connection with the Class D Warrant Inducement included in accounts payable
     
    $
    25,968

    $
    —

    Fair Value of Class D Common Stock Warrants in connection with the February 2024 Public Offering
     
    $
    6,269,684

    $
    —

    Fair Value of Class C Common Stock Warrants in connection with the February 2023 Public Offering
     
    $
    —

    $
    13,996,500

    Alternative cashless exercise of Class C Common Stock Warrants
     
    $
    57,589

    $
    5,526,287

    Deferred offering costs included in accounts payable and accrued expenses
     
    $
    —

    $
    66,033

See accompanying notes to the consolidated financial statements.

 F-7

REVELATION BIOSCIENCES, INC. 

Notes to the Consolidated Financial Statements

1. Organization and Basis of PresentationRevelation Biosciences, Inc. (collectively with its wholly-owned subsidiaries, referred to as “we,” us,” “our,” “Revelation,” or the “Company”) is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention for acute kidney injury (“AKI”), GEM-CKD as a treatment for chronic kidney disease (“CKD”), and GEM-PSI as a prevention for post surgical infection (“PSI”). The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California.The Company’s common stock and public warrants are listed on the Nasdaq Capital Market under the symbols “REVB” and “REVBW”, respectively.Reverse Stock Splits On January 17, 2025, the Company filed a Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation effecting a reverse stock split on January 28, 2025 with a ratio of 1-for-16 (the “2025 Reverse Split”). As a result of the 2025 Reverse